ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Management Failures

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Dec 03, 2020 8:49pm

140 Views

Post# 32034280

RE:Management Failures

This is something I think could pursued further in the new year. Do you have any examples of companies that are or have used this formula where their CEO , President are paid based on performance. Just wondering if it has worked out and how is it structured.

Thanks in advance.

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute